Moshe Shoham - Microbot Medical Director
| MBOT Stock | USD 0.88 0.02 2.33% |
Director
Dr. Moshe Shoham, D.Sc., is Director of the Company. He is a cofounder of Microbot Israel and has served as Chairman of Microbot Israels Scientific Advisor Board and as a Director since Microbot Israel was founded in November 2010. Prof. Shoham was the head of the robotics laboratory at the TechnionIsrael Institute of Technology, Department of Mechanical Engineering since October 1990 and was a professor in the Department of Mechanical Engineering at the TechnionIsrael Institute of Technology since October 1989. Prior to that, Dr. Shoham was the director of the robotic laboratory in the Department of Mechanical Engineering at Columbia University from September 1986 to September 1989. Dr. Shoham has served as a foreign member of the National Academy of Engineering in the United States since October 2014. In addition, Dr. Shoham founded Mazor Surgical Technologies Ltd., a publically traded medical device company in the field of surgical robotics, and was its Chief Technology Officer since January 2003. Dr. Shoham earned B.Sc. in 1978, a M.Sc. in 1982 and a D.Sc. in 1986 from the TechnionIsrael Institute of Technology. since 2016.
| Age | 64 |
| Tenure | 8 years |
| Address | 288 Grove Street, Braintree, MA, United States, 02184 |
| Phone | 781 875 3605 |
| Web | https://www.microbotmedical.com |
Microbot Medical Management Efficiency
The company has return on total asset (ROA) of (0.6896) % which means that it has lost $0.6896 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8219) %, meaning that it created substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.23 in 2024. Return On Capital Employed is likely to gain to -2.06 in 2024. Total Current Liabilities is likely to gain to about 4.8 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 7.9 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| MD FCAP | Predictive Oncology | N/A | |
| Jack Wareham | ResMed Inc | 76 | |
| Deborah Tanner | West Pharmaceutical Services | 57 | |
| Myla LaiGoldman | West Pharmaceutical Services | 62 | |
| James Orr | Becton Dickinson and | 70 | |
| Alfred Sommer | Becton Dickinson and | 71 | |
| Andrew Eckert | Becton Dickinson and | 56 | |
| Basil Anderson | Becton Dickinson and | 70 | |
| William Wall | STAAR Surgical | 55 | |
| Eric Halvorson | Intuitive Surgical | 64 | |
| Richard Sulpizio | ResMed Inc | 70 | |
| Amy Ladd | Intuitive Surgical | N/A | |
| Mark Buthman | West Pharmaceutical Services | 60 | |
| John Weiland | West Pharmaceutical Services | 61 | |
| Agnes Lee | ResMed Inc | N/A | |
| Paolo Pucci | West Pharmaceutical Services | 59 | |
| Jeffrey Henderson | Becton Dickinson and | 56 | |
| Gary Pace | ResMed Inc | 69 | |
| John Wareham | ResMed Inc | 73 | |
| Mark Rubash | Intuitive Surgical | 61 | |
| Harjit Gill | ResMed Inc | 55 | |
Management Performance
| Return On Equity | -1.82 | ||||
| Return On Asset | -0.69 |
Microbot Medical Leadership Team
Elected by the shareholders, the Microbot Medical's board of directors comprises two types of representatives: Microbot Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Microbot. The board's role is to monitor Microbot Medical's management team and ensure that shareholders' interests are well served. Microbot Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Microbot Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Prattipati Laxminarain, Independent Director | ||
| Yoav Waizer, Director | ||
| Simon Sharon, CTO | ||
| Rachel Vaknin, Chief Officer | ||
| Harel Gadot, Chairman of the Board and Presidentident, CEO | ||
| Yoseph Bornstein, COFounder Director | ||
| Eyal MD, Chief Board | ||
| MSc MBA, CTO Israel | ||
| Pr DSc, Scientific CoFounder | ||
| Juan DiazCartelle, Chief Officer | ||
| Solomon Mayer, Director | ||
| David Naim, CFO | ||
| Moshe Shoham, Director | ||
| Yehezkel Himelfarb, COO, General Manager - Israeli Operations | ||
| Scott Burell, Director | ||
| Martin Madden, Independent Director |
Microbot Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Microbot Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.82 | ||||
| Return On Asset | -0.69 | ||||
| Current Valuation | 6.52 M | ||||
| Shares Outstanding | 14.4 M | ||||
| Shares Owned By Insiders | 1.68 % | ||||
| Shares Owned By Institutions | 12.26 % | ||||
| Number Of Shares Shorted | 255.37 K | ||||
| Price To Earning | (3.42) X | ||||
| Price To Book | 3.23 X | ||||
| EBITDA | (9.75 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Microbot Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Microbot Medical's short interest history, or implied volatility extrapolated from Microbot Medical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Microbot Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Microbot Stock please use our How to Invest in Microbot Medical guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Microbot Stock analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Microbot Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Microbot Medical. If investors know Microbot will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Microbot Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Return On Assets (0.69) | Return On Equity (1.82) |
The market value of Microbot Medical is measured differently than its book value, which is the value of Microbot that is recorded on the company's balance sheet. Investors also form their own opinion of Microbot Medical's value that differs from its market value or its book value, called intrinsic value, which is Microbot Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Microbot Medical's market value can be influenced by many factors that don't directly affect Microbot Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Microbot Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Microbot Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Microbot Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.